# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Stifel analyst Bradley Canino maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and raises the price target from $14 to...
PLTR: 8% | Palantir Technologies shares are trading higher amid its addition to the S&P 500 index. TERN: 42% | Terns Pharma...
Summit Therapeutics shared Phase 3 HARMONi-2 trial data of ivonescimab, showing significant improvement in progression-free sur...
HC Wainwright & Co. analyst Mitchell Kapoor maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and raises the price ...
Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First...
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Summit Therapeutics (NASDAQ:SMMT) with a Buy and maintains $16 pr...